Request Sample
Request Methodology
Description
The global immunosuppressants market size expected to reach $41,511.37 million by 2026, at a CAGR of 14.2% during forecast period 2021-2026. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in the organ transplantation, autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others. Moreover, immunosuppressants also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis. Immunodeficiency is the major adverse effect associated with the immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects with the immunosuppressants. Immunosuppressants market is growing at a significant CAGR owing to increase in the prevalence of autoimmune disorders and incidence of organ transplantation. For instance, According to World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was increased about 1.8% from 2013. Furthermore, various pipeline products in the market also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies for increasing their revenue in immunosuppressants market. For instance, in July 2015, Veloxis Pharmaceuticals A/S received FDA approval for Envarsus XR used for the prophylaxis of rejection in the kidney transplant patients. Moreover, in October 2016, Cadila Healthcare partnered with Neovii to launch an immunosuppressants in India market.
